These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 29471567)

  • 1. Targeting Hepatitis D.
    Rizzetto M
    Semin Liver Dis; 2018 Feb; 38(1):66-72. PubMed ID: 29471567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational drugs in development for Hepatitis D.
    Rizzetto M
    Expert Opin Investig Drugs; 2017 Sep; 26(9):999-1005. PubMed ID: 28730878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hepatitis D: an unmet medical need.
    Caviglia GP; Rizzetto M
    Clin Microbiol Infect; 2020 Jul; 26(7):824-827. PubMed ID: 32120043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic Hepatitis D; at a Standstill?
    Rizzetto M
    Dig Dis; 2016; 34(4):303-7. PubMed ID: 27170382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistent Control of Hepatitis B Virus and Hepatitis Delta Virus Infection Following REP 2139-Ca and Pegylated Interferon Therapy in Chronic Hepatitis B Virus/Hepatitis Delta Virus Coinfection.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Anderson M; Gersch J; Holzmayer V; Elsner C; Krawczyk A; Kuhns MC; Cloherty G; Dittmer U; Vaillant A
    Hepatol Commun; 2021 Feb; 5(2):189-202. PubMed ID: 33553968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current management of delta hepatitis.
    Rizzetto M
    Liver Int; 2013 Feb; 33 Suppl 1():195-7. PubMed ID: 23286865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative analysis of hepatitis D virus RNA and hepatitis B surface antigen serum levels in chronic delta hepatitis improves treatment monitoring.
    Manesis EK; Schina M; Le Gal F; Agelopoulou O; Papaioannou C; Kalligeros C; Arseniou V; Manolakopoulos S; Hadziyannis ES; Gault E; Koskinas J; Papatheodoridis G; Archimandritis AJ
    Antivir Ther; 2007; 12(3):381-8. PubMed ID: 17591028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response.
    Niro GA; Smedile A; Fontana R; Olivero A; Ciancio A; Valvano MR; Pittaluga F; Coppola N; Wedemeyer H; Zachou K; Marrone A; Fasano M; Lotti G; Andreone P; Iacobellis A; Andriulli A; Rizzetto M
    Aliment Pharmacol Ther; 2016 Sep; 44(6):620-8. PubMed ID: 27443972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future treatments for hepatitis delta virus infection.
    Asselah T; Loureiro D; Tout I; Castelnau C; Boyer N; Marcellin P; Mansouri A
    Liver Int; 2020 Feb; 40 Suppl 1():54-60. PubMed ID: 32077603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up.
    Castelnau C; Le Gal F; Ripault MP; Gordien E; Martinot-Peignoux M; Boyer N; Pham BN; Maylin S; Bedossa P; Dény P; Marcellin P; Gault E
    Hepatology; 2006 Sep; 44(3):728-35. PubMed ID: 16941695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of delta hepatitis.
    Gunsar F
    Expert Rev Anti Infect Ther; 2013 May; 11(5):489-98. PubMed ID: 23627855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hepatitis delta: Need for novel therapeutic options.
    Abbas Z; Abbas M
    World J Gastroenterol; 2015 Aug; 21(32):9461-5. PubMed ID: 26327754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.
    Keskin O; Wedemeyer H; Tüzün A; Zachou K; Deda X; Dalekos GN; Heidrich B; Pehlivan S; Zeuzem S; Yalçın K; Gürel S; Tabak F; Idilman R; Bozkaya H; Manns M; Yurdaydin C
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2342-49.e1-2. PubMed ID: 26044319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options.
    Lempp FA; Ni Y; Urban S
    Nat Rev Gastroenterol Hepatol; 2016 Oct; 13(10):580-9. PubMed ID: 27534692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.
    Lutterkort GL; Wranke A; Hengst J; Yurdaydin C; Stift J; Bremer B; Hardtke S; Keskin O; Idilman R; Manns MP; Dienes HP; Falk C; Wedemeyer H; Heidrich B
    J Viral Hepat; 2018 Nov; 25(11):1384-1394. PubMed ID: 29888837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment.
    Grabowski J; Yurdaydìn C; Zachou K; Buggisch P; Hofmann WP; Jaroszewicz J; Schlaphoff V; Manns MP; Cornberg M; Wedemeyer H;
    Liver Int; 2011 Oct; 31(9):1395-405. PubMed ID: 21762356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis delta and HIV infection.
    Soriano V; Sherman KE; Barreiro P
    AIDS; 2017 Apr; 31(7):875-884. PubMed ID: 28121714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HBsAg isoform dynamics during NAP-based therapy of HBeAg-negative chronic HBV and HBV/HDV infection.
    Bazinet M; Anderson M; Pântea V; Placinta G; Moscalu I; Cebotarescu V; Cojuhari L; Jimbei P; Iarovoi L; Smesnoi V; Musteata T; Jucov A; Dittmer U; Gersch J; Holzmayer V; Kuhns M; Cloherty G; Vaillant A
    Hepatol Commun; 2022 Aug; 6(8):1870-1880. PubMed ID: 35368148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.
    Bogomolov P; Alexandrov A; Voronkova N; Macievich M; Kokina K; Petrachenkova M; Lehr T; Lempp FA; Wedemeyer H; Haag M; Schwab M; Haefeli WE; Blank A; Urban S
    J Hepatol; 2016 Sep; 65(3):490-8. PubMed ID: 27132170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.